Canopus Biopharma and leading chinese researcher, Dr. Jiahai Lu, team up to treat avian influenza with StatC, to prevent possible pandemic. An internationally renowned avian influenza expert today hailed encouraging and exciting results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC™ in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model. Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University in Guangzhou, China, has published extensively in the field of avian influenza, and has been researching the breakthrough compound StatC™ for the past two years on behalf of Canopus BioPharma (OTCPK:CBIA), a US corporation who discovered and patented the potential of this antiviral candidate.